FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4249870096> ?p ?o ?g. }

• W4249870096 endingPage "1450" @default.
• W4249870096 startingPage "1450" @default.
• W4249870096 abstract "Abstract Background: We have previously described that EGF blocks the activity of EGFR tyrosine kinase inhibitors (EGFR-TKIs) in EGFR mutant NSCLC cells, an effect that is reversed by anti-EGF antibodies generated by vaccination (anti-EGF VacAbs) (1). In this study we aimed to determine the effect of EGF and anti-EGF Vac Abs in the activity of different kinase inhibitors in tumor cell lines with different genetic alterations. Methods: Anti-EGF VacAbs were obtained by immunizing rabbits with recombinant EGF. The cell lines used in this study were H2228 and H3122 (NSCLC, EML4-ALK positive), H23 (NSCLC, KRAS-G12C), DLD1 (colorectal carcinoma, KRAS-G13D), PC9 and PC9-GR4 (NSCLC, EGFR-mut). Tumor cell lines were treated with EGF, anti-EGF VacAbs and combinations with the kinase inhibitors alectinib, crizotinib, brigatinib (ALK inhibitors), trametinib (MEK inhibitor), dacomitinib and osimertinib (EGFR inhibitors). Cell viability was analyzed by MTT, changes of total and phosphorylated proteins were determined by Western blot and emergence of resistance by direct microscopic examination in low density cultures. Results: EGF significantly decreased the antitumor activity of alectinib, crizotinib and brigatinib in ALK translocated cells (H2228 and H3122), trametinib in KRAS mutant cells (H23 and DLD1) and osimertinib and dacomitinib in EGFR mutant cells (PC9). In combination with these TKIs, the anti-EGF VacAbs reversed the effects of EGF and significantly potentiated the antitumor activity of all the kinase inhibitors, blocking the activation of EGFR, Akt and Erk. Finally, the addition of the anti-EGF VacAbs to the culture medium delayed the appearance of resistant clones to kinase inhibitors. Conclusions: Anti-EGF VacAbs potentiate the antitumor effects of ALK, MEK and EGFR kinase inhibitors in tumor cell lines and delay the emergence of resistance in vitro. A clinical trial is currently testing anti-EGF vaccination in combination with afatinib in EGFR-mut advanced NSCLC patients.(1)Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells” Codony-Servat J, García-Roman S, Molina-Vila MÁ, et al. J Thorac Oncol. 2018. Citation Format: Jordi Codony-Servat, Silvia Garcia-Roman, Miguel Ángel Molina-Vila, Jordi Bertran-Alamillo, Ana Giménez-Capitán, Santiago Viteri, Andrés F. Cardona, Delvys Rodríguez, Manuel Cobo, Noemi Reguart, Niki Karachaliou, Erik d'Hondt, Rafael Rosell. Anti-EGF antibodies generated by vaccination significantly improve the activity of kinase inhibitors in preclinical models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1450." @default.
• W4249870096 created "2022-05-12" @default.
• W4249870096 creator A5014155408 @default.
• W4249870096 creator A5021472595 @default.
• W4249870096 creator A5027946288 @default.
• W4249870096 creator A5028890927 @default.
• W4249870096 creator A5039171238 @default.
• W4249870096 creator A5040541281 @default.
• W4249870096 creator A5044887899 @default.
• W4249870096 creator A5056676096 @default.
• W4249870096 creator A5071798228 @default.
• W4249870096 creator A5084359163 @default.
• W4249870096 creator A5087391532 @default.
• W4249870096 creator A5088157561 @default.
• W4249870096 creator A5090598248 @default.
• W4249870096 date "2019-07-01" @default.
• W4249870096 modified "2023-10-18" @default.
• W4249870096 title "Abstract 1450: Anti-EGF antibodies generated by vaccination significantly improve the activity of kinase inhibitors in preclinical models" @default.
• W4249870096 doi "https://doi.org/10.1158/1538-7445.am2019-1450" @default.
• W4249870096 hasPublicationYear "2019" @default.
• W4249870096 type Work @default.
• W4249870096 citedByCount "0" @default.
• W4249870096 crossrefType "journal-article" @default.
• W4249870096 hasAuthorship W4249870096A5014155408 @default.
• W4249870096 hasAuthorship W4249870096A5021472595 @default.
• W4249870096 hasAuthorship W4249870096A5027946288 @default.
• W4249870096 hasAuthorship W4249870096A5028890927 @default.
• W4249870096 hasAuthorship W4249870096A5039171238 @default.
• W4249870096 hasAuthorship W4249870096A5040541281 @default.
• W4249870096 hasAuthorship W4249870096A5044887899 @default.
• W4249870096 hasAuthorship W4249870096A5056676096 @default.
• W4249870096 hasAuthorship W4249870096A5071798228 @default.
• W4249870096 hasAuthorship W4249870096A5084359163 @default.
• W4249870096 hasAuthorship W4249870096A5087391532 @default.
• W4249870096 hasAuthorship W4249870096A5088157561 @default.
• W4249870096 hasAuthorship W4249870096A5090598248 @default.
• W4249870096 hasConcept C121608353 @default.
• W4249870096 hasConcept C126322002 @default.
• W4249870096 hasConcept C170493617 @default.
• W4249870096 hasConcept C184235292 @default.
• W4249870096 hasConcept C185592680 @default.
• W4249870096 hasConcept C199649820 @default.
• W4249870096 hasConcept C2776232967 @default.
• W4249870096 hasConcept C2776256026 @default.
• W4249870096 hasConcept C2776362946 @default.
• W4249870096 hasConcept C2777626846 @default.
• W4249870096 hasConcept C2778087573 @default.
• W4249870096 hasConcept C2778472372 @default.
• W4249870096 hasConcept C2779422266 @default.
• W4249870096 hasConcept C2779438470 @default.
• W4249870096 hasConcept C2781187634 @default.
• W4249870096 hasConcept C42362537 @default.
• W4249870096 hasConcept C502942594 @default.
• W4249870096 hasConcept C526805850 @default.
• W4249870096 hasConcept C55493867 @default.
• W4249870096 hasConcept C57074206 @default.
• W4249870096 hasConcept C71924100 @default.
• W4249870096 hasConcept C82495950 @default.
• W4249870096 hasConcept C97029542 @default.
• W4249870096 hasConcept C98274493 @default.
• W4249870096 hasConceptScore W4249870096C121608353 @default.
• W4249870096 hasConceptScore W4249870096C126322002 @default.
• W4249870096 hasConceptScore W4249870096C170493617 @default.
• W4249870096 hasConceptScore W4249870096C184235292 @default.
• W4249870096 hasConceptScore W4249870096C185592680 @default.
• W4249870096 hasConceptScore W4249870096C199649820 @default.
• W4249870096 hasConceptScore W4249870096C2776232967 @default.
• W4249870096 hasConceptScore W4249870096C2776256026 @default.
• W4249870096 hasConceptScore W4249870096C2776362946 @default.
• W4249870096 hasConceptScore W4249870096C2777626846 @default.
• W4249870096 hasConceptScore W4249870096C2778087573 @default.
• W4249870096 hasConceptScore W4249870096C2778472372 @default.
• W4249870096 hasConceptScore W4249870096C2779422266 @default.
• W4249870096 hasConceptScore W4249870096C2779438470 @default.
• W4249870096 hasConceptScore W4249870096C2781187634 @default.
• W4249870096 hasConceptScore W4249870096C42362537 @default.
• W4249870096 hasConceptScore W4249870096C502942594 @default.
• W4249870096 hasConceptScore W4249870096C526805850 @default.
• W4249870096 hasConceptScore W4249870096C55493867 @default.
• W4249870096 hasConceptScore W4249870096C57074206 @default.
• W4249870096 hasConceptScore W4249870096C71924100 @default.
• W4249870096 hasConceptScore W4249870096C82495950 @default.
• W4249870096 hasConceptScore W4249870096C97029542 @default.
• W4249870096 hasConceptScore W4249870096C98274493 @default.
• W4249870096 hasIssue "13_Supplement" @default.
• W4249870096 hasLocation W42498700961 @default.
• W4249870096 hasOpenAccess W4249870096 @default.
• W4249870096 hasPrimaryLocation W42498700961 @default.
• W4249870096 hasRelatedWork W1889913689 @default.
• W4249870096 hasRelatedWork W2546236621 @default.
• W4249870096 hasRelatedWork W2562253741 @default.
• W4249870096 hasRelatedWork W3152767218 @default.
• W4249870096 hasRelatedWork W3167107489 @default.
• W4249870096 hasRelatedWork W3172491611 @default.
• W4249870096 hasRelatedWork W3207592456 @default.
• W4249870096 hasRelatedWork W4210382341 @default.
• W4249870096 hasRelatedWork W4293104804 @default.
• W4249870096 hasRelatedWork W2565765257 @default.

• next